Eftersom busulfan har udvist potentiale for tumorgenicitet i forsøg hos mennesker og dyr, skal amning indstilles før behandlingens start.
Because of the potential for tumorigenicity shown for busulfan in human and animal studies, breast-feeding should be discontinued at the start of therapy.